JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB251526

Anti-N2,N2-dimethylguanosine (m2,2G) 抗体 [EPR-19838-40] - BSA and Azide free

Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40] - BSA and Azide free

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Recombinant Monoclonal N2,N2-dimethylguanosine (m2,2G) antibody. Carrier free. Suitable for IP, ELISA, Dot and reacts with Modified Nucleic Acid samples. Cited in 1 publication.

別名を表示する

Di-m2G, N2,N2-dimethylguanosine, m22G

4 Images
Immunoprecipitation - Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40] - BSA and Azide free (AB251526)
  • IP

Supplier Data

Immunoprecipitation - Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40] - BSA and Azide free (AB251526)

This data was developed using ab211488, the same antibody clone in a different buffer formulation.

The IP was performed in a U-bottom non-adsorbing propylene 96-well plate.

ab211488 (0.2 μg) was coated into Dynabeads® sheep-anti-rabbit IgG (50 μl) for 1h at RT.

Unmodified/modified oligonucleotides (5 μM) were added to samples containing the antibody/bead complexes and incubated with agitation for 1 hour at RT.

After washing, Peroxidase-conjugated Streptavidin was incubated at 1/1000 dilution with agitation for 1 hour at RT.

ECL substrate was then added and the results read in a non-transparent 96-well plate with a digital detector and analyzed using ImageJ.

Lane 1 : Buffer only.

Lane 2 : Modified oligonucleotide (5 μM), 5' Biotin-mN.mN.mN.mN.mN.[m2,2G]*.mN.mN.mN.mN.mN 3'

Lane 3 : Unmodified oligonucleotide (5 μM), 5' Biotin-mN.mN.mN.mN.mN.[G]*.mN.mN.mN.mN.mN 3'

N - equimolar mixture of (A/U/G/C)
m - 2'O methyl protection
* - phosphorothioate protection

Blocking buffer : 5% NFDM/TBST

Dilution buffer : TBST/0.1% Triton X-100/1 mM EDTA.

All lanes:

Immunoprecipitation - Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40] (<a href='/products/primary-antibodies/n2n2-dimethylguanosine-m22g-antibody-epr-19838-40-ab211488'>ab211488</a>)

true

ELISA - Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40] - BSA and Azide free (AB251526)
  • ELISA

Supplier Data

ELISA - Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40] - BSA and Azide free (AB251526)

This data was developed using ab211488, the same antibody clone in a different buffer formulation.

BSA-conjugated m2,2G (modified) and G (unmodified) nucleosides were coated onto wells of a 96 well plate. ELISA was performed on 1.0 μg/ml of antigen using ab211488 at a concentration range of 0.005-4.000 μg/ml, followed by Goat Anti-Rabbit IgG, (H+L), alkaline phosphatase conjugated secondary antibody at 1/2500 dilution.

Dot Blot - Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40] - BSA and Azide free (AB251526)
  • Dot

Lab

Dot Blot - Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40] - BSA and Azide free (AB251526)

This data was developed using ab211488, the same antibody clone in a different buffer formulation.

Primary antibody dilution : 1/500

Secondary antibody : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated

Secondary antibody dilution : 1/100,000

Blocking and dilution buffer : AdvanBlockTM Chemi Blocking buffer

Input : Biotin-m2.2G oligo 2 ng per Dot

Competitive nucleosides : m2.2G, m2G, m1G

Exposure times : 37 seconds

Dot Blot - Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40] - BSA and Azide free (AB251526)
  • Dot

Lab

Dot Blot - Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40] - BSA and Azide free (AB251526)

This data was developed using ab211488, the same antibody clone in a different buffer formulation.

Lane 1 : Yeast tRNA
Lane 2 : Biotin-m2.2G RNA oligo
Lane 3 : Biotin-G RNA oligo

Primary antibody dilution : 1/500

Secondary antibody : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated

Secondary antibody dilution : 1/20,000

Blocking and dilution buffer : AdvanBlockTM Chemi Blocking buffer

関連する標識済み抗体及び組成の異なる製品 (1)

  • Unconjugated

    Anti-N2,N2-dimethylguanosine (m2,2G) antibody [EPR-19838-40]

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR-19838-40

アイソタイプ

IgG

キャリアフリー

Yes

アプリケーション

Dot, IP, ELISA

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

特異性

Has been developed to discriminate between the modified base N2,N2-dimethylguanosine (m2,2G) and the unmodified counterpart Guanosine (G).

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Modified Nucleic Acid": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "ELISA-species-checked": "testedAndGuaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "<p></p>", "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "<p></p>" } } }

製品の詳細

ab251526 is the carrier-free version of ab211488.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.2 - 7.4 Constituents: PBS
出荷温度
Blue Ice
短期保存温度
+4°C
長期保存温度
+4°C
保管に関する情報
Do Not Freeze

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

N2N2-dimethylguanosine (m22G) is a modified nucleoside found in various types of RNA including tRNA and rRNA. It plays a role in the cellular machinery by contributing to the structural stability and function of RNA molecules. Its mass is approximately 297 g/mol. Expression of m22G occurs in the cellular RNA of many organisms reflecting its essential role in RNA structure. The modification m22G often referred to as a methylated derivative of guanosine is implicated in numerous cellular processes due to its presence in key RNA components.
Biological function summary

The modification of guanine at the N2 position influences RNA stability and function by enhancing the efficiency of translation. It forms part of the ribosome's active sites appearing as part of larger ribonucleoprotein complexes which are important for carrying out protein synthesis. This modification helps maintain the correct structure of ribosomal RNA ensuring accurate and efficient protein production. The presence of m22G in RNA components aids in the prevention of frameshift mutations during translation marking its importance in maintaining genetic fidelity.

Pathways

M22G plays a significant role in the translation and protein synthesis pathway contributing to the proper assembly and function of ribosomes. The presence of m22G within these pathways ensures the proper execution of genetic code translation interacting closely with proteins like ribosomal protein S15 and other translational machinery components. These interactions are essential in coordinating the synthesis of proteins impacting cellular growth and development functions.

M22G has connections with certain cancers and neurological disorders due to its involvement in regulating RNA stability and translation efficiency. Alterations or dysregulation in the patterns of m22G methylation can contribute to carcinogenesis by affecting the accuracy of protein translation. Proteins involved in this dysregulation include ribosomal proteins and RNA methyltransferases which can lead to the development of malignant transformation. Additionally insufficient or aberrant methylation of guanosine can contribute to neurodegenerative diseases like Alzheimer's where impaired RNA function results from transcriptional and translational inefficiencies.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

文献 (1)

Recent publications for all applications. Explore the full list and refine your search

Oncology letters 18:545-552 PubMed31289526

2019

Lymphoepithelioma-like gastric carcinoma treated with partial gastrectomy: Two case reports.

Applications

Unspecified application

Species

Unspecified reactive species

Huihua Cao,Jun Xie,Yongxiang Qian,Yugang Wu,Zhaoqing Tang
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com